Lack of association of tumor-associated macrophages with clinical outcome in patients with classical Hodgkin's lymphoma

A recent study demonstrated that an increased number of CD68+ macrophages were correlated with primary treatment failure, shortened progression-free survival (PFS) and disease-specific survival (DSS) in patients with classical Hodgkin's lymphoma (cHL). The aim of the present study was to verify...

Full description

Saved in:
Bibliographic Details
Published inAnnals of oncology Vol. 23; no. 3; p. 736
Main Authors Azambuja, D, Natkunam, Y, Biasoli, I, Lossos, I S, Anderson, M W, Morais, J C, Spector, N
Format Journal Article
LanguageEnglish
Published England 01.03.2012
Subjects
macrophages
CD68
prognosis
Hodgkin's lymphoma
Online AccessGet full text

Cover

More Information
Summary:A recent study demonstrated that an increased number of CD68+ macrophages were correlated with primary treatment failure, shortened progression-free survival (PFS) and disease-specific survival (DSS) in patients with classical Hodgkin's lymphoma (cHL). The aim of the present study was to verify the relationship between the number of CD68+ and CD163+ macrophages with clinical outcomes in a cohort of 265 well-characterized patients with cHL treated uniformly with the standard doxorubicin, bleomycin, vinblastine and dacarbazine chemotherapy regimen. Two pairs of hematopathologists carried out independent pathological evaluations of tissue microarray slides. There were no associations between clinical characteristics and the expression of CD68 or CD163. However, higher levels of CD68 and CD163 expression were correlated with the presence of Epstein-Barr virus-positive Hodgkin tumor cells (P = 0.01 and 0.037, respectively). The expression of CD68 or CD163 was not associated with either the PFS or the DSS. CD68 and CD163 expression require further evaluation before their use can be recommended for prognostic stratification of patients with cHL.
ISSN:1569-8041